Boy Died Following Denied Drug Coverage
Mason Henderson, who had a rare brain tumor, died on May 4, 2026, after initial insurance delays for a prescribed medication.
Updated on Sept. 21, 2026 in Cancer
Mason Henderson, a Houston patient with diffuse hemispheric glioma, died on May 4, 2026. His family faced a month-long battle to secure Lynparza after an insurance denial.
Why it matters
Insurers frequently deny coverage for off-label prescriptions, creating life-threatening barriers for patients with rare diseases that lack specific FDA-approved treatments.
Lynparza carries a monthly cost of approximately $8,700, and physicians prescribed the drug based on the tumor's specific genetic language. The treatment was sought after 90% of the patient's tumor was removed.
The players
Mason Henderson
A patient diagnosed with the rare brain condition diffuse hemispheric glioma who received treatment in Houston.
Liviniti
A pharmacy benefit manager that denied insurance coverage for the prescribed medication on January 30, 2026.
AstraZeneca
The pharmaceutical company that manufactures Lynparza and eventually provided a donation of the medication after an appeal.
The details
After the insurer Liviniti denied coverage on Jan. 30, 2026, the family turned to social media to campaign for the medication. AstraZeneca eventually provided a bottle of 60 pills following a successful appeal, allowing the patient to take the drug for nearly two months.
Timeline
Jan 16, 2026: The drug was prescribed by doctors.
Jan 30, 2026: Liviniti refused coverage for the treatment.
March 2026: AstraZeneca initially denied a donation request.
March 9, 2026: AstraZeneca approved the shipment of the medication.
May 4, 2026: Mason Henderson died.
The Big Picture
This case follows a recurring pattern where insurers withhold coverage for treatments lacking an FDA label for a patient's specific diagnosis. This conflict highlights the ongoing friction between clinical need and the FDA off-label drug prescribing guidelines in oncology.
Families facing insurance denials for life-saving drugs may find success through direct appeals to pharmaceutical companies or public advocacy. This case illustrates that even with an appeal, the timeline for securing medication can be critical for patient outcomes.
The takeaway
Navigating pharmacy benefit managers often requires immediate advocacy to overcome coverage barriers. Patients and families can sometimes secure access through compassionate use programs or manufacturer assistance when traditional insurance fails.
Further reading
Learn more about the challenges of treatment access in the Cancer section.
